Tony Wood, GSK CSO
August 22, 2024 11:00 AM EDT
People
R&D
Pharma

Q&A: GSK CSO Tony Wood on stay­ing out of obe­si­ty, 'care­ful' can­cer am­bi­tions, and AI's fu­ture in R&D

Andrew Dunn

Senior Biopharma Correspondent

When Tony Wood be­came GSK’s top sci­en­tist in mid-2022, the British phar­ma was wag­ing bat­tle.

GSK was fight­ing Zan­tac-re­lat­ed lit­i­ga­tion in court while strug­gling to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

A service from the Financial Times